Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Jul 9 · inside the Ichimoku cloud · RSI 57 · MACD below its signal
None of the 29 investors followed here reported a position in VICA in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a VICA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for VICA.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 33.3 | 25.0 | 140.0 | -41.7 | 42.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | +233.3% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 200.0 | 0.0 | 0.0 | +200.0% |
| 2024 | 0.0 | 0.0 | -93.3 | 0.0 | 2900.0 | 0.0 | -96.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −93.3% |
| 2023 | 13.3 | 5.9 | -41.7 | 71.4 | -66.7 | -16.7 | -20.0 | 0.0 | -25.0 | -66.7 | 100.0 | 650.0 | 0.0% |
| 2022 | -3.6 | 16.0 | -44.7 | 32.4 | 27.8 | -10.0 | -26.6 | -42.1 | -29.5 | 4.8 | -26.2 | -37.5 | −86.4% |
| 2021 | -30.2 | 1.6 | 203.3 | 0.8 | -49.2 | -36.6 | 36.7 | -46.3 | 2.3 | -23.3 | -45.2 | -22.5 | −82.9% |
| 2020 | 25.0 | -57.0 | -5.8 | 4.0 | -52.5 | 25.0 | 60.0 | -47.5 | 0.0 | 261.9 | 0.0 | -15.1 | −19.4% |
| 2019 | -57.1 | 160.7 | -39.4 | -44.3 | -12.9 | 25.2 | -22.9 | 4.3 | 3.6 | -40.8 | -26.3 | 53.0 | −77.1% |
| 2018 | 66.7 | -16.8 | 10.2 | -18.2 | 11.1 | 100.0 | -35.0 | 10.0 | -40.6 | -41.2 | 0.0 | -30.0 | −51.4% |
| 2017 | -74.1 | -30.0 | -4.8 | 18.7 | 5.3 | -25.0 | 6.6 | -50.0 | -23.7 | -17.5 | -10.7 | -19.8 | −96.1% |
| 2016 | 4.9 | -0.6 | -2.4 | 9.1 | 23.3 | 0.0 | 0.0 | -5.4 | -7.1 | 25.1 | 34.4 | -43.6 | +14.2% |
| 2015 | -9.7 | 15.0 | 27.3 | 7.3 | 2.3 | 8.9 | -6.1 | 12.6 | 1.4 | 8.0 | -2.5 | 2.5 | +82.9% |
| 2014 | 0.0 | 60.0 | -20.0 | -25.0 | 0.0 | 12.5 | 11.1 | 56.7 | 2.1 | -12.5 | 42.9 | 3.3 | +148.0% |
| 2013 | -7.4 | 0.0 | −7.4% |
No analyst coverage for this instrument.
Rafina Innovations Inc. engages in the research, development, commercialization, and marketing of medical technologies. It operates through two segments, Clinics and Technology. The company also operates prosthetics and orthotics, and diabetic foot total rehabilitation clinics in Southern Europe, the Middle East, and North Africa. In addition, it is involved in the research, development, and commercialization of medical devices, methods, and products in the fields of prosthetics, orthotics, rehabilitation, bioengineering, mobility, diabetes, diabetic foot, tissue mechanics, ultrasonics, medical signal processing and analysis, medical technology, orthopedics, and robotic surgery; and licensing of its proprietary technologies. The company was formerly known as HCi Viocare and changed its name to Rafina Innovations Inc. in July 2018. Rafina Innovations Inc. was founded in 2007 and is based in Glasgow, the United Kingdom.
No recent headlines.